Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
An FDA advisory panel has voted 16 to 0 to recommend approval of icosapent ethyl as add-on treatment to statins to lower risk for cardiovascular (CV) events in high-risk patients, Reuters reports.
Icosapent ethyl (marketed as Vascepa) is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid. It was first approved in 2012 to lower triglycerides in adults with levels of 500 mg/dL or higher.
The panel discussed last year's REDUCE-IT trial, in which nearly 8200 statin-treated patients with CV disease or diabetes and fasting triglycerides between 135 and 499 mg/dL were randomized to icosapent ethyl or placebo. During roughly 5 years' follow-up, risk for major CV events was 25% lower with icosapent ethyl.
The FDA advisers were "largely in favor" of expanding approval to patients with histories of CV disease, Reuters reports, but some were unsure of the benefits in those without such histories.
The FDA is not required to follow its advisers' recommendations, but it usually does so.
Comment
LINK(S):
Reuters story (Free)
Background: NEJM Journal Watch Cardiology coverage of REDUCE-IT (Free)